This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Doronin, K.
Right arrow Articles by Wold, W. S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Doronin, K.
Right arrow Articles by Wold, W. S. M.

 Previous Article  |  Next Article 

Journal of Virology, July 2000, p. 6147-6155, Vol. 74, No. 13
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein

Konstantin Doronin, Karoly Toth, Mohan Kuppuswamy, Peter Ward, Ann E. Tollefson, and William S. M. Wold*

Department of Molecular Microbiology and Immunology, St. Louis University School of Medicine, St. Louis, Missouri

Received 10 December 1999/Accepted 28 March 2000

We have constructed two novel adenovirus (Ad) replication-competent vectors, named KD1 and KD3, that may have use in anticancer therapy. The vectors have two key features. First, they markedly overexpress the Ad death protein (ADP), an Ad nuclear membrane glycoprotein required at late stages of infection for efficient cell lysis and release of Ad from cells. Overexpression of ADP was achieved by deleting the E3 region and reinserting the adp gene. Because ADP is overexpressed, KD1 and KD3 are expected to spread more rapidly and effectively through tumors. Second, KD1 and KD3 have two E1A mutations (from the mutant dl1101/1107) that prevent efficient replication in nondividing cells but allow replication in dividing cancer cells. These E1A mutations preclude binding of E1A proteins to p300 and pRB. As a result, the virus should not be able to drive cells from G0 to S phase and therefore should not be able to replicate in normal tissues. We show that KD1 and KD3 do not replicate well in quiescent HEL-299 cells or in primary human bronchial epithelial cells, small airway epithelial cells, or endothelial cells; however, they replicate well in proliferating HEL-299 cells and human A549 lung carcinoma cells. In cultured A549 cells, KD1 and KD3 lyse cells and spread from cell to cell more rapidly than their control virus, dl1101/1107, or wild-type Ad. They are also more efficient than dl1101/1107 or wild-type Ad in complementing the spread from cell to cell of an E1- E3- replication-defective vector expressing beta -galactosidase. A549 cells form rapidly growing solid tumors when injected into the hind flanks of immunodeficient nude mice; however, when A549 cells were infected with 10-4 PFU of KD3/cell prior to injection into mice, tumor formation was nearly completely suppressed. When established A549 tumors in nude mice were examined, tumors injected with buffer grew 13.3-fold over 5 weeks, tumors injected with dl1101/1107 grew 8-fold, and tumors injected with KD1 or KD3 grew 2.6-fold. Hep 3B tumors injected with buffer grew 12-fold over 3.5 weeks, whereas tumors injected with KD1 or KD3 grew 4-fold. We conclude that KD1 and KD3 show promise as anticancer therapeutics.

* Corresponding author. Mailing address: Department of Molecular Microbiology and Immunology, St. Louis University School of Medicine, St. Louis, MO 63104. Phone: (314) 577-8435. Fax: (314) 773-3403. E-mail: woldws{at}slu.edu.

Journal of Virology, July 2000, p. 6147-6155, Vol. 74, No. 13
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Gros, A., Martinez-Quintanilla, J., Puig, C., Guedan, S., Mollevi, D. G., Alemany, R., Cascallo, M. (2008). Bioselection of a Gain of Function Mutation that Enhances Adenovirus 5 Release and Improves Its Antitumoral Potency. Cancer Res. 68: 8928-8937 [Abstract] [Full Text]  
  • Shashkova, E. V., Doronin, K., Senac, J. S., Barry, M. A. (2008). Macrophage Depletion Combined with Anticoagulant Therapy Increases Therapeutic Window of Systemic Treatment with Oncolytic Adenovirus. Cancer Res. 68: 5896-5904 [Abstract] [Full Text]  
  • Tollefson, A. E., Ying, B., Doronin, K., Sidor, P. D., Wold, W. S. M. (2007). Identification of a New Human Adenovirus Protein Encoded by a Novel Late l-Strand Transcription Unit. J. Virol. 81: 12918-12926 [Abstract] [Full Text]  
  • Wohlfahrt, M. E., Beard, B. C., Lieber, A., Kiem, H.-P. (2007). A Capsid-Modified, Conditionally Replicating Oncolytic Adenovirus Vector Expressing TRAIL Leads to Enhanced Cancer Cell Killing in Human Glioblastoma Models. Cancer Res. 67: 8783-8790 [Abstract] [Full Text]  
  • Zhang, Y.-A., Nemunaitis, J., Samuel, S. K., Chen, P., Shen, Y., Tong, A. W. (2006). Antitumor Activity of an Oncolytic Adenovirus-Delivered Oncogene Small Interfering RNA. Cancer Res. 66: 9736-9743 [Abstract] [Full Text]  
  • Glockzin, G., Mantwill, K., Jurchott, K., Bernshausen, A., Ladhoff, A., Royer, H.-D., Gansbacher, B., Holm, P. S. (2006). Characterization of the Recombinant Adenovirus Vector AdYB-1: Implications for Oncolytic Vector Development.. J. Virol. 80: 3904-3911 [Abstract] [Full Text]  
  • Zhu, M., Bristol, J. A., Xie, Y., Mina, M., Ji, H., Forry-Schaudies, S., Ennist, D. L. (2005). Linked Tumor-Selective Virus Replication and Transgene Expression from E3-Containing Oncolytic Adenoviruses. J. Virol. 79: 5455-5465 [Abstract] [Full Text]  
  • Toth, K., Djeha, H., Ying, B., Tollefson, A. E., Kuppuswamy, M., Doronin, K., Krajcsi, P., Lipinski, K., Wrighton, C. J., Wold, W. S. M. (2004). An Oncolytic Adenovirus Vector Combining Enhanced Cell-to-Cell Spreading, Mediated by the ADP Cytolytic Protein, with Selective Replication in Cancer Cells with Deregulated Wnt Signaling. Cancer Res. 64: 3638-3644 [Abstract] [Full Text]  
  • Fukuda, K., Abei, M., Ugai, H., Seo, E., Wakayama, M., Murata, T., Todoroki, T., Tanaka, N., Hamada, H., Yokoyama, K. K. (2003). E1A, E1B Double-restricted Adenovirus for Oncolytic Gene Therapy of Gallbladder Cancer. Cancer Res. 63: 4434-4440 [Abstract] [Full Text]  
  • Tollefson, A. E., Scaria, A., Ying, B., Wold, W. S. M. (2003). Mutations within the ADP (E3-11.6K) Protein Alter Processing and Localization of ADP and the Kinetics of Cell Lysis of Adenovirus-Infected Cells. J. Virol. 77: 7764-7778 [Abstract] [Full Text]  
  • Jakubczak, J. L., Ryan, P., Gorziglia, M., Clarke, L., Hawkins, L. K., Hay, C., Huang, Y., Kaloss, M., Marinov, A., Phipps, S., Pinkstaff, A., Shirley, P., Skripchenko, Y., Stewart, D., Forry-Schaudies, S., Hallenbeck, P. L. (2003). An Oncolytic Adenovirus Selective for Retinoblastoma Tumor Suppressor Protein Pathway-defective Tumors: Dependence on E1A, the E2F-1 Promoter, and Viral Replication for Selectivity and Efficacy. Cancer Res. 63: 1490-1499 [Abstract] [Full Text]  
  • Wein, L. M., Wu, J. T., Kirn, D. H. (2003). Validation and Analysis of a Mathematical Model of a Replication-competent Oncolytic Virus for Cancer Treatment: Implications for Virus Design and Delivery. Cancer Res. 63: 1317-1324 [Abstract] [Full Text]  
  • Bernt, K. M., Steinwaerder, D. S., Ni, S., Li, Z.-Y., Roffler, S. R., Lieber, A. (2002). Enzyme-activated Prodrug Therapy Enhances Tumor-specific Replication of Adenovirus Vectors. Cancer Res. 62: 6089-6098 [Abstract] [Full Text]  
  • Suzuki, K., Alemany, R., Yamamoto, M., Curiel, D. T. (2002). The Presence of the Adenovirus E3 Region Improves the Oncolytic Potency of Conditionally Replicative Adenoviruses. Clin. Cancer Res. 8: 3348-3359 [Abstract] [Full Text]  
  • Bernt, K., Liang, M., Ye, X., Ni, S., Li, Z.-Y., Ye, S. L., Hu, F., Lieber, A. (2002). A New Type of Adenovirus Vector That Utilizes Homologous Recombination To Achieve Tumor-Specific Replication. J. Virol. 76: 10994-11002 [Abstract] [Full Text]  
  • Nettelbeck, D. M., Rivera, A. A., Balague, C., Alemany, R., Curiel, D. T. (2002). Novel Oncolytic Adenoviruses Targeted to Melanoma: Specific Viral Replication and Cytolysis by Expression of E1A Mutants from the Tyrosinase Enhancer/Promoter. Cancer Res. 62: 4663-4670 [Abstract] [Full Text]  
  • Tsukuda, K., Wiewrodt, R., Molnar-Kimber, K., Jovanovic, V. P., Amin, K. M. (2002). An E2F-responsive Replication-selective Adenovirus Targeted to the Defective Cell Cycle in Cancer Cells: Potent Antitumoral Efficacy but No Toxicity to Normal Cell. Cancer Res. 62: 3438-3447 [Abstract] [Full Text]  
  • Ring, C. J. A. (2002). Cytolytic viruses as potential anti-cancer agents. J. Gen. Virol. 83: 491-502 [Abstract] [Full Text]  
  • Koch, P., Gatfield, J., Lober, C., Hobom, U., Lenz-Stoppler, C., Roth, J., Dobbelstein, M. (2001). Efficient Replication of Adenovirus Despite the Overexpression of Active and Nondegradable p53. Cancer Res. 61: 5941-5947 [Abstract] [Full Text]  
  • Matsubara, S., Wada, Y., Gardner, T. A., Egawa, M., Park, M.-S., Hsieh, C.-L., Zhau, H. E., Kao, C., Kamidono, S., Gillenwater, J. Y., Chung, L. W. K. (2001). A Conditional Replication-competent Adenoviral Vector, Ad-OC-E1a, to Cotarget Prostate Cancer and Bone Stroma in an Experimental Model of Androgen-independent Prostate Cancer Bone Metastasis. Cancer Res. 61: 6012-6019 [Abstract] [Full Text]  
  • Lam, P. Y.P., Breakefield, X. O. (2001). Potential of gene therapy for brain tumors. Hum Mol Genet 10: 777-787 [Abstract] [Full Text]  
  • Doronin, K., Kuppuswamy, M., Toth, K., Tollefson, A. E., Krajcsi, P., Krougliak, V., Wold, W. S. M. (2001). Tissue-Specific, Tumor-Selective, Replication-Competent Adenovirus Vector for Cancer Gene Therapy. J. Virol. 75: 3314-3324 [Abstract] [Full Text]  
  • Brunori, M., Malerba, M., Kashiwazaki, H., Iggo, R. (2001). Replicating Adenoviruses That Target Tumors with Constitutive Activation of the wnt Signaling Pathway. J. Virol. 75: 2857-2865 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»